Lever
Lifestyle
- Regular exercise
- Adequate hydration
- Smoking cessation
Blutwerte · Marker
eGFR
Estimated GFR · Glomeruläre Filtrationsrate · GFR · CKD-EPI
Nierenwerte
- Einheit:
- mL/min/1.73 m2
eGFR quantifies the rate of blood filtration by the kidneys, estimated from serum creatinine levels.
Reference Ranges
Age Group
Reference
60–120mL/min/1.73 m2
60
120
LowNormalHigh
Reference
Unit · mL/min/1.73 m2Values below 60 mL/min/1.73 m2 suggest kidney dysfunction. Age and sex can influence eGFR.
Overview
Übersicht
The estimated glomerular filtration rate (eGFR) is a calculated value used to assess kidney function by estimating the rate at which the kidneys filter waste from the blood. It is derived from serum creatinine levels, age, sex, and sometimes race, using specific equations. Clinically, eGFR is a critical marker for diagnosing and monitoring chronic kidney disease (CKD), reflecting the kidneys' ability to filter blood and remove waste products. Researchers have found that eGFR is particularly useful in identifying early stages of CKD, where intervention can prevent progression to more severe kidney damage. In the context of athletic performance and biohacking, maintaining an optimal eGFR is important for overall health, as impaired kidney function can affect physical performance and recovery. However, eGFR can be influenced by factors such as muscle mass, diet, and hydration status, which may confound results. Researchers observed that time of day and fasting status do not significantly affect eGFR, but recent intense exercise can temporarily alter creatinine levels, impacting eGFR calculations.
Klinische Bedeutung
Elevated eGFR values are generally not a concern, but reduced eGFR indicates impaired kidney function, potentially signaling chronic kidney disease or acute kidney injury.
Dynamics
Trend Interpretation
Rising Values
Progressively rising eGFR values are generally not concerning unless they indicate hyperfiltration, which can occur in early diabetic kidney disease. Re-test if clinical suspicion exists.
Falling Values
Progressively falling eGFR values suggest worsening kidney function and may require intervention.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- High muscle mass
- High protein diet
- Dehydration
- Pregnancy
- Use of certain medications
- Acute illness
Cause
Low Levels
- Chronic kidney disease
- Acute kidney injury
- Heart failure
- Liver disease
- Diabetes
- Hypertension
Protocol
How to Optimize
Lever
Nutrition
- Balanced diet
- Reduced sodium intake
- Moderate protein consumption
Note:
Consult a healthcare provider before making significant dietary or lifestyle changes, especially if kidney disease is present.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for healthy adults, more frequently if CKD is suspected or diagnosed.
Interfering Factors
- Recent intense exercise
- High protein intake
- Dehydration
Related Peptides & Hormones
Cystatin C
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that the clinical significance of uncommon EGFR mutations in non-small cell lung cancer remains understudied, particularly regarding their response to tyrosine kinase inhibitors. Researchers have not yet established optimal reference ranges for eGFR in diverse populations, which complicates its use in chronic kidney disease assessment. Additionally, unanswered clinical questions include the efficacy of targeting HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer and the best strategies for managing patients with these mutations.
38 Research Publications
9,047
Total Citations
19
Human/RCT
48.3
Avg. Influence
2026
Latest
Sort
Filter
01Top
#01
Revised equations for estimated GFR from serum creatinine in Japan.
HumanInfluence459.0
6141
This study developed new equations for estimating glomerular filtration rate (eGFR) in Japanese patients. Researchers found that the new equations provide more accurate estimates compared to previous models, particularly for patients with chronic kidney disease. The study highlights the importance of using a central laboratory for consistent results.
02Top
#02
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
HumanInfluence67.0
1560
Researchers analyzed the overall survival outcomes of patients with advanced non-small-cell lung cancer based on their epidermal growth factor receptor (EGFR) mutation status. They found no significant difference in survival between treatments with gefitinib and carboplatin/paclitaxel overall, but noted that EGFR mutations were strong predictors of progression-free survival. The study highlighted the complexity of treatment responses based on biomarker status.
03Top
#03
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Meta-AnalysisInfluence30.0
491
This workshop evaluated the use of changes in albuminuria and glomerular filtration rate (GFR) as endpoints in clinical trials for chronic kidney disease. Researchers found that both measures can serve as surrogate endpoints under specific conditions, with a stronger case for using GFR changes. The study emphasizes the need for careful implementation in clinical trial design.
04
#04
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
UnknownInfluence8.0
288
This study focused on the implementation of EGFR mutation testing in non-small cell lung cancer across Europe. Researchers found that standardized testing procedures are crucial for optimizing the use of EGFR tyrosine kinase inhibitors in clinical practice. The workshop emphasized the importance of timely testing and appropriate sampling techniques.
05
#05
Cystatin C as a biomarker of chronic kidney disease: latest developments.
ReviewInfluence8.0
187
Researchers assessed the use of serum cystatin C as a biomarker for chronic kidney disease (CKD). They found that cystatin C is a reliable early indicator of CKD, especially in patients where traditional markers like creatinine are insufficient. The study emphasizes the need for standardization in eGFR equations to improve patient care.
06
#06
A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population.
HumanInfluence1.0
69
Researchers developed a new panel for estimating glomerular filtration rate (eGFR) that includes β2-Microglobulin and β-Trace Protein without requiring race specification. The study found that this 4-marker panel is as accurate as traditional methods that include race.
07
#07
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
ReviewInfluence1.0
56
This review provided an overview of EGFR-targeted therapies in cancer treatment. Researchers highlighted the mechanisms of resistance to current EGFR inhibitors and the importance of personalized predictive approaches. The study underscores the need for ongoing research to develop more effective multi-targeting agents and combination therapies to overcome resistance.
08
#08
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.
HumanInfluence1.0
38
This study investigated the relationship between kidney function, measured by eGFR, and blood biomarkers for Alzheimer's disease (AD). Researchers observed that impaired kidney function was associated with higher levels of certain biomarkers, but these associations diminished when adjusting for age and sex. The findings suggest that eGFR has limited impact on the predictive value of AD biomarkers.
09
#09
Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
HumanInfluence1.0
37
This study evaluated the use of serum KL-6 levels in predicting interstitial lung disease induced by EGFR-TKIs in patients with non-small cell lung cancer. Researchers observed that changes in KL-6 levels could distinguish between survivors and non-survivors of life-threatening ILD.
10
#10
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
ReviewInfluence1.0
35
Researchers reviewed the role of HER2 amplification in resistance to anti-EGFR therapy in metastatic colorectal cancer. They found that HER2 amplification is associated with poor prognosis and may serve as a negative predictor for treatment efficacy. The study suggests that targeting HER2 could change treatment strategies for a subset of patients.
Clinical Trials (29)
29
Total Trials
3,273
Total Enrolled
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
Sponsor
NYU Langone Health
Enrollment
60
Started
2026
Primary outcome
Proportion of Patients Achieving Complete Clearance of Plasma EGFR Mutations
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients
NCT07718308NOT_YET_RECRUITING
Sponsor
wujianyong
Enrollment
20
Started
2026
Primary outcome
Slope of estimated glomerular filtration rate (eGFR) decline
Kidney TransplantationAntibody-mediated Rejection
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Sponsor
University of Wisconsin, Madison
Enrollment
80
Started
2026
Primary outcome
Average Epidermal Growth Factor Receptor (EGFR) expression level
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Sponsor
Beijing Biotech
Enrollment
60
Started
2026
Primary outcome
Incidence of dose-limiting toxicities (DLTs)
Non-Small Cell Lung CancerAdvanced/Metastatic
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
Sponsor
Yonsei University
Enrollment
85
Started
2025
Primary outcome
Overall Response Rate
RAS/BRAF Wild-type Advanced Colorectal Cancer Patients
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
Sponsor
Peking Union Medical College Hospital
Enrollment
37
Started
2023
Primary outcome
progression free survival 1 (PFS1)
Non Small Cell Lung CancerImmune Checkpoint InhibitorEGFR Exon 21 Mutation
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Enrollment
82
Started
2023
Primary outcome
Unbound BDTX-1535 Concentration in Tumor Tissue
High Grade GliomaGlioblastoma
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719RECRUITING
Sponsor
Sun Yat-sen University
Enrollment
150
Started
2023
Primary outcome
Intratumor heterogeneity (ITH)
Non-small Cell Lung Cancer
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
NCT05482100UNKNOWN
Sponsor
Transplant Genomics, Inc.
Enrollment
500
Started
2022
Primary outcome
GFR changes between study group and matched control group
Kidney Transplant Rejection
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Sponsor
Alessandro Doria
Enrollment
40
Started
2022
Primary outcome
Baseline-adjusted iGFR at 8 weeks after randomization
Diabetic Nephropathies
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment
56
Started
2021
Primary outcome
Objective response rate (ORR)
Non-small Cell Lung Cancer Stage III
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Sponsor
Mark Vincent
Enrollment
200
Started
2021
Primary outcome
Objective Response Rate according to Response Evaluation Criteria in Solid Tumors version 1.1
Non-Small Cell Lung Cancer
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
6
Started
2020
Primary outcome
Overall Response Rate
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Sponsor
Seattle Children's Hospital
Enrollment
44
Started
2019
Primary outcome
Estimate the maximum tolerated dose (MTD) or biologically effective dose and dose limiting toxicities (DLT), and describe the full toxicity profile of the two CAR T cell products
Pediatric Solid TumorGerm Cell TumorRetinoblastomaHepatoblastomaWilms TumorRhabdoid TumorCarcinomaOsteosarcomaEwing SarcomaRhabdomyosarcomaSynovial SarcomaClear Cell SarcomaMalignant Peripheral Nerve Sheath TumorsDesmoplastic Small Round Cell TumorSoft Tissue SarcomaNeuroblastoma
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Enrollment
440
Started
2019
Primary outcome
OS
Non-small Cell Lung Cancer
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
Sponsor
Nantes University Hospital
Enrollment
150
Started
2019
Primary outcome
Examination of the genetic profile at the point of disease progression in EGFRm+ (mutated Epidermal Growth Factor Receptor) patients receiving osimertinib as first-line EGFR TKI therapy compared to baseline.
Non-small Cell Lung Cancer
Renal Function Assessment in Critically Ill Children
NCT05179564COMPLETED
Sponsor
University Hospital, Ghent
Enrollment
100
Started
2018
Primary outcome
Agreement between determination of GFR when based on biomarker formulas to estimate GFR compared to measurement of GFR by iohexol plasma clearance
IohexolPharmacokineticsRenal FunctionCritically Ill ChildrenAcute Kidney InjuryAugmented Renal Clearance
Prednisolone Treatment in Acute Interstitial Nephritis
Sponsor
Region MidtJylland Denmark
Enrollment
110
Started
2017
Primary outcome
eGFR
Acute Tubulo-Interstitial Nephritis
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor
Vanderbilt-Ingram Cancer Center
Enrollment
22
Started
2017
Primary outcome
Maximum tolerated dose experience a dose-limiting toxicity
Non-Small Cell Lung Carcinoma
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
NCT02136862COMPLETED
Sponsor
Genzyme, a Sanofi Company
Enrollment
165
Started
2014
Primary outcome
To characterize the natural decline of renal function markers (Glomerular Filtration Rate [GFR] and creatinine) in patients with Alport syndrome over the course of up to 120 weeks
Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
NCT01978314COMPLETED
Sponsor
FAST BioMedical
Enrollment
33
Started
2013
Primary outcome
Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function
Chronic Kidney DiseaseAcute Kidney Injury
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Sponsor
Gilead Sciences
Enrollment
252
Started
2013
Primary outcome
Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24
HIVHIV Infections
Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
NCT01759862COMPLETED
Sponsor
Stanford University
Enrollment
50
Started
2012
Primary outcome
Calculated Estimated Glomerular Filtration Rate (eGFR)
Function of Renal Transplant
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Sponsor
Symphogen A/S
Enrollment
26
Started
2011
Primary outcome
Progression Free Survival (PFS) Time
Carcinoma, Squamous Cell of Head and Neck
Kidney Damage in Patients With Normal eGFR
Sponsor
Bracco Diagnostics, Inc
Enrollment
49
Started
2010
Primary outcome
Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media.
Coronary Artery Stenosis
Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.
NCT01260038COMPLETED
Sponsor
University Hospital, Antwerp
Enrollment
107
Started
2010
Primary outcome
testing turn around time (in days)
Non Small Cell Lung Cancer
Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD
NCT01194518COMPLETED
Sponsor
National Cheng Kung University
Enrollment
120
Started
2010
Primary outcome
The Results of eGFR at Each Time Poins From Baseline to 6, 12, 18, 24, and 30 Months
Chronic Kidney DiseasesHealth BehaviorsPatient Education
Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
NCT01124669COMPLETED
Sponsor
ECOG-ACRIN Cancer Research Group
Enrollment
80
Started
2010
Primary outcome
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
Lung Cancer
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Sponsor
Swiss Cancer Institute
Enrollment
149
Started
2010
Primary outcome
Progression-free survival at 6 months in stratum wtEGFR cohort 1
Lung Cancer
Publication Trend
Research publications about eGFR over time
4totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer